Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

COPD: Update Bulletin [November 2014]

Product Code:
596200305
Release Date:
November 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in COPD: triple fixed-dose combination products, the WISDOM trial (steroid withdrawal) results, tiotropium/olodaterol and the potential role of anti-IL5 antibodies in COPD.

Highlights from this event update bulletin

  • What are the advantages and disadvantages of ICS/LAMA/LABA combinations?
  • What proportion of COPD patients could be prescribed ICS/LAMA/LABAs?
  • Could ICS/LAMA/LABAs be more successful than LAMA/LABA combinations?
  • Will the WISDOM trial results change clinical practice and encourage uptake of LABA/LAMAs?
  • Could tiotropium/olodaterol emerge as the leading LABA/LAMA?
  • Do anti-IL5 antibodies have a role in COPD?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved